Curcumin
Curcumin (Turmeric extract)
Generic anti-inflammatory rationale; no AGA-specific RCT support and abysmal oral bioavailability.
How Curcumin works — and how well we know it
Polyphenolic compound with broad anti-inflammatory and antioxidant activity in vitro. Separately, curcumin shows modest anti-androgen activity in vitro and in prostate-cancer models — it down-regulates androgen receptor expression and blocks AR-driven transcription (Tsui 2008) — though this has never been demonstrated in hair follicles or at concentrations achievable from oral supplementation. Notoriously low oral bioavailability — often paired with piperine in supplements to improve absorption, though even then plasma levels remain low.
oral, topical
500–1,000 mg/day oral (with piperine for absorption). Topical formulations exist but lack standardized dosing.
Available as a dietary supplement. Marketed for general anti-inflammatory benefits; included in Nutrafol and Vegamour blends.
General anti-inflammatory support; not a targeted AGA intervention.
Evidence distribution across 1 claims
Why the grade is D. Anti-inflammatory mechanism is plausible but generic. No AGA-specific RCT support. One small topical hair-growth study with mixed methodology.
Every claim, traced back to its source
We took every major claim made about Curcumin and matched it to the specific experimental model behind it. Click a claim to see the model, the finding, and our assessment of how much weight it deserves.
1 claims · evidence-by-evidence breakdown
1In VitroWeight: LowCurcumin has broad anti-inflammatory activity in vitro, but very low oral bioavailabilityAnti-inflammatory in vitro; the path from that to actual hair growth in humans has not been demonstrated.
Cell culture studies of NF-kB pathway inhibition by curcumin.
Curcumin inhibits inflammatory cascades in cell culture at concentrations far higher than achievable from oral supplementation without piperine.
The anti-inflammatory mechanism is real in vitro. Translating that to AGA requires (a) reaching the scalp follicle in meaningful concentration and (b) demonstrating that inflammation reduction affects AGA-specific outcomes. Neither has been shown.
- Aggarwal BB, Harikumar KB (2009). Int J Biochem Cell Biol PMID 18662800
What's still missing from the science
- RCT of oral curcumin for AGA outcomes.
- RCT of topical curcumin formulations.
- Bioavailability data for the doses in commercial hair supplements.
Our verdict on Curcumin
Not in our formulary yet
We don't carry this ingredient. We only formulate around actives where the evidence — and the safety profile — is strong enough to recommend with confidence. As the data matures, we may revisit.
Related treatments
How does Curcumin stack up against its closest peers?
A genuine cause of reversible hair shedding in iron-deficient patients — but useless and potentially harmful if your iron stores are normal.
Read the breakdown →A botanical 5-alpha reductase inhibitor whose only high-quality trials (in BPH) showed no benefit over placebo; the positive AGA data are small and low-quality.
Read the breakdown →One small Malaysian RCT showed a hair-count increase. Never replicated. Used by Nutrafol to justify its tocotrienol content.
Read the breakdown →